Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 85 Florida 70 Colorado 41 Texas 40 Massachusetts 39
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca5 Pfizer4 Eli Lilly and Company3 Olema Pharmaceuticals, Inc.3 Criterium, Inc.2
State
California85 Florida70 Colorado41 Texas40 Massachusetts39
All 47 states
Target enrolment
to

Trials with a site in Colorado

41 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
DrugsRGT-419B·Giredestrant·Abemaciclib
Genentech, Inc.
Phase 1/2
285
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maine
2025-10-07
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381HER2-positive Breast Cancer, Breast Cancer
DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel
Jazz Pharmaceuticals
Phase 2
125
California, Colorado, Florida, Iowa, Louisiana, Maine, Maryland, Michigan
2025-09-24
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
DrugDisitamab Vedotin
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-30
Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394Breast Neoplasms, Breast Cancer
DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib
Pfizer
Phase 3
1,035
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
285
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Active, closed
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Breast Cancer
DrugsVepdegestrant·Atirmociclib
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Eribulin·Herceptin·Trastuzumab
Criterium, Inc.
Phase 2
17
Colorado, District of Columbia, New Mexico, Washington, Wisconsin
2024-01-30
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDato-DXd·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2023-06-07
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
DrugsKeytruda·Pembrolizumab
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139Breast Cancer, Solid Tumors, Adult
DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Active, closed
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532Breast Cancer
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Greenwich LifeSciences, Inc.
Phase 3
2,250
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-16
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
DrugsDato-DXd·Xeloda·Durvalumab·Keytruda
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
DrugsPalazestrant·Atirmociclib·Alpelisib·Everolimus
Olema Pharmaceuticals, Inc.
Phase 1
190
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2022-08-31
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Michigan
2022-05-16
Active, closed
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
180
California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York
2022-02-15
Recruiting
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Active, closed
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
California, Colorado, Illinois, Kentucky, Maryland, Nebraska, New York, Ohio
2021-07-01
Active, closed
Breast Cancer Index (BCI) Registry
NCT04875351Breast Cancer
Biotheranostics, Inc.
Observational
3,465
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, New York
2021-04-14
Active, closed
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420Breast Cancer
DrugsPalbociclib·Fulvestrant
Criterium, Inc.
Phase 2
70
Arizona, California, Colorado, Connecticut, Georgia, Louisiana, Nebraska, New Mexico
2021-02-09
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
California, Colorado, Illinois, Michigan, New York, North Carolina, Tennessee
2020-07-01
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
DrugsEpirubicin·Adriamycin·Cytoxan·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,240
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-12-27
Active, closed
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT03332797Breast Cancer
DrugsGiredestrant·Palbociclib
Genentech, Inc.
Phase 1
181
Colorado, Massachusetts, New York, Tennessee
2017-11-24
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Recruiting
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193Breast Cancer
Agendia
Observational
30,000
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2017-04-28
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751Non Small Cell Lung Cancer, Breast Cancer
DrugsAnastrozole·Abemaciclib·Pembrolizumab
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
DrugEntrectinib
Hoffmann-La Roche
Phase 2
534
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2015-11-19
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Colorado that also match the filters currently applied.

How many clinical trials are recruiting in Colorado?

16 of the 41 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorado), 41 studies
PhaseStudiesRecruitingShare
Phase 316739%
Phase 19122%
Phase 1/28419.5%
Phase 25212.2%
Observational327.3%

Most active sponsors

Lead sponsors with the most studies (Colorado)
Lead sponsorStudiesRecruiting
AstraZeneca51
Pfizer41
Eli Lilly and Company31
Olema Pharmaceuticals, Inc.31
Criterium, Inc.20
Genentech, Inc.21
Hoffmann-La Roche21
Jazz Pharmaceuticals22
Merck Sharp & Dohme LLC21
Relay Therapeutics, Inc.22
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.